Yale Identifies 2 Proteins Driving Parkinson's Spread in 1.1 Million Americans
Updated
Updated · SciTechDaily · May 10
Yale Identifies 2 Proteins Driving Parkinson's Spread in 1.1 Million Americans
5 articles · Updated · SciTechDaily · May 10
mGluR4 and NPDC1, two neuron-surface proteins, were identified by Yale researchers as key entry points that let misfolded α-synuclein move into healthy brain cells and fuel Parkinson’s progression.
4,400 engineered cell groups were screened for α-synuclein binding; only 16 surface proteins bound it, and mGluR4 and NPDC1 stood out because they are present in dopamine neurons of the substantia nigra.
Mouse experiments strengthened the link: disabling either protein blunted α-synuclein buildup, reduced Parkinson’s-like symptoms, and in a disease model lowered death risk while slowing symptom worsening.
The findings, published in Nature Communications, point to a treatment strategy aimed at blocking α-synuclein spread rather than only easing symptoms in a disease affecting about 1.1 million Americans.
Blocking two proteins could halt Parkinson's, but what essential brain functions might we be sacrificing in the process?
Will blocking two proteins in the brain truly stop Parkinson's if the disease actually originates and spreads from the gut?
With other promising drugs already in human trials, which new therapy offers the best hope for finally halting Parkinson's progression?
Blocking mGluR4-NPDC1 Complex Halts Alpha-Synuclein Spread: A Paradigm Shift in Parkinson’s Disease Treatment
Overview
In late 2025, Yale researchers made a major breakthrough in understanding how Parkinson's disease spreads in the brain. They screened plasma membrane proteins and discovered that two key proteins, mGluR4 and NPDC1, are highly expressed in dopamine neurons that are lost in Parkinson's. These proteins act as high-affinity binding sites for toxic, misfolded alpha-synuclein, helping it move from cell to cell and drive disease progression. Removing mGluR4 and NPDC1 in mice protected their dopamine neurons, highlighting these proteins as promising new targets for therapies that could slow or stop Parkinson's disease.